0001562180-22-005918.txt : 20220805
0001562180-22-005918.hdr.sgml : 20220805
20220805161240
ACCESSION NUMBER: 0001562180-22-005918
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220803
FILED AS OF DATE: 20220805
DATE AS OF CHANGE: 20220805
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOORE JOHN R
CENTRAL INDEX KEY: 0001191702
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 221140969
MAIL ADDRESS:
STREET 1: 3200 WALNUT ST
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc.
CENTRAL INDEX KEY: 0001710072
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 821725586
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3415 COLORADO AVE.
CITY: BOULDER
STATE: CO
ZIP: 80303
BUSINESS PHONE: 303-735-8373
MAIL ADDRESS:
STREET 1: 3415 COLORADO AVE.
CITY: BOULDER
STATE: CO
ZIP: 80303
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-08-03
false
0001710072
Edgewise Therapeutics, Inc.
EWTX
0001191702
MOORE JOHN R
C/O EDGEWISE THERAPEUTICS, INC.
3145 COLORADO AVE
BOULDER
CO
80303
false
true
false
false
General Counsel
Common Stock
2022-08-03
4
M
false
4730.00
1.93
A
7730.00
D
Common Stock
2022-08-03
4
M
false
4502.00
0.71
A
12232.00
D
Common Stock
2022-08-03
4
S
false
9232.00
9.3069
D
3000.00
D
Stock Option (Right to Buy)
1.93
2022-08-03
4
M
false
4730.00
0.00
D
2030-12-15
Common Stock
4730.00
132457.00
D
Stock Option (Right to Buy)
0.71
2022-08-03
4
M
false
4502.00
0.00
D
2030-09-01
Common Stock
4502.00
112558.00
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date.
1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.
/s/ John R. Moore
2022-08-05